Dirk Arnold, MD | Authors


Dr. Dirk Arnold on Sirflox and its Effect on Liver Metastases

October 28, 2015

Dirk Arnold, MD, PhD, Professor and Head Dept. Hematology and Medical Oncology at Tumor Biology Center in Freiburg, Germany, talks about sirflox and its phase III trials on whether or not it can properly add local ablative treatment to diffuse metastasization of the liver.

Advantages of Using Y-90 for the First-Line Treatment of Patients With Liver Metastases from mCRC

July 24, 2015

Dirk Arnold, MD, director of the Department of Medical Oncology at Klinik für Tumorbiologie, Freiburg, Germany, discusses the advantages of using yttrium-90 (Y-90) as the first line treatment for patients with liver metastases from metastatic colorectal cancer (mCRC).